摘要:
The invention concerns 14,17-C2-bridged steroids of general formula (I), wherein: R3 represents an oxygen atom, the hydroxy amino group or two hydrogen atoms; R6 represents either a hydrogen, fluorine, chlorine or bromine atom or a C¿1?-C4 alkyl group at the α or β position, R?6' and R7¿ then representing hydrogen atoms; or alternatively, R6 represents a hydrogen, fluorine, chlorine or bromine atom or a C¿1?-C4 alkyl group, R?6' and R7¿ then representing a common additional bond; R7 represents a C¿1?-C4 alkyl group at the α or β position, R?6 and R6'¿ then representing hydrogen atoms; or alternatively R?6 and R7¿ together represent a methylene group at the α or β position and R6' represents a hydrogen atom; or R?6 and R6'¿ together represent an ethylene or methylene group and R7 represents a hydrogen atom; R?9 and R10¿ each represent a hydrogen atom or a common bond; R?11 and R12¿ each represent a hydrogen atom or a common bond; R13 represents a methyl or ethyl group; R15 represents a hydrogen atom or a C¿1?-C3 alkyl group; R?16 and R16'¿ independently of one another represent a hydrogen atom, a C¿1?-C3 alkyl group, or a C2-C4 alkenyl group, or together represent a C1-C3 alkylidene group; R?15 and R16¿ represent a common bond and R16' represents a hydrogen atom or a C¿1?-C3 alkyl group, or alternatively R?15 and R16¿ together represent a ring of the partial formula (i) shown, in which n = 1 and 2 and X represents a methylene group or an oxygen atom; and R16' represents a hydrogen atom; R171 represents a hydrogen atom or a C¿1?-C3 alkyl group; R17?2¿ represents a hydrogen atom, a C¿1?-C3 alkyl group or a C2-C4 alkenyl group; R17?1'¿ and R172' each represent a hydrogen atom or a common bond; R21 represents a hydrogen atom or a C¿1?-C3 alkyl group; and R?21'¿ represents a hydrogen atom, C¿1?-C3 alkyl group or hydroxy group. The claimed compounds do not include 14,17-ethano-19-norpregn-4-en-3,20-dione. The novel compounds, unlike the one disclaimed, show a high level of gestagenic activity even after peroral administration and are suitable for use in the production of medicaments.
摘要:
Described are etheno- and ethano-19,11-bridged 4-estrenes of general formula (I), in which W, R?1, R2, R6a, R6b, R7, R14, R15, R16, R11, R11' and R19¿ are as defined in the description. Also described is a method of preparing them. These compounds exhibit a marked gestagenic action and are suitable for use in the production of drugs.
摘要:
Described are etheno- and ethano-19,11-bridged 4-estrenes of general formula (I), in which W, R , R , R , R , R , R , R , R , R , R and R are as defined in the description. Also described is a method of preparing them. These compounds exhibit a marked gestagenic action and are suitable for use in the production of drugs.
摘要:
The invention relates to the novel benzimidazole derivatives of formula (I), to the production and use thereof in the treatment and prophylaxis of diseases that are associated with microglial activation, and of T-cell mediated immunological diseases. The invention also relates to the pharmaceutical preparations that contain the novel benzimidazole derivatives.
摘要:
The invention relates to novel benzimidazole derivatives with general formula (I), whereby the radicals R?1, R2, R3¿, A, B, Y and Z have the meanings as cited in the description and in the claims. The invention also relates to the use of these compounds for producing a medicament used for the treatment and prophylaxis of diseases associated with a microglia-activation, and to pharmaceutical preparations containing these compounds.
摘要:
The invention relates to novel benzimidazole derivatives of general formula (I), wherein the groups R?1, R2, R3¿, A, B and Y are defined as per the definition and the claims. The invention also relates to the use of these compounds for producing a medicament for the prophylaxis and treatment of diseases linked to the activation of microglia and to pharmaceutical preparations containing said compounds.
标题翻译:BENZIMIDAZOLDERIVATE ZUR BEHANDLUNG VON MIT MIKROGLIA-AKTIVIERUNG ASSOZIIERTEN ERKRANKUNGEN WIE INFLAMMATORISCHE,ALLERGISCHE,INFEKTIÖSEODER AUTOIMMUNE ERKRANKUNGEN
摘要:
The invention relates to novel benzimidazole derivatives with general formula (I), whereby the radicals R?1, R2, R3¿, A, B, Y and Z have the meanings as cited in the description and in the claims. The invention also relates to the use of these compounds for producing a medicament used for the treatment and prophylaxis of diseases associated with a microglia-activation, and to pharmaceutical preparations containing these compounds.
摘要:
The invention relates to novel benzimidazole derivatives with general formula (I), whereby the radicals R?1, R2, R3¿, A, B, Y and Z have the meanings as cited in the description and in the claims. The invention also relates to the use of these compounds for producing a medicament used for the treatment and prophylaxis of diseases associated with a microglia-activation, and to pharmaceutical preparations containing these compounds.
摘要:
The invention relates to the use of microglia inhibitors for producing medicaments that inhibit the monocyte, macrophage and T cell-induced immune reactions, and to their use for treating T cell-induced immunological diseases and inflammatory reactions that are not T-cell induced.
摘要:
The invention relates to 1,2-diaryl benzimidazoles of general formula (I) and to the use of benzimidazole derivatives for producing medicaments utilized for the treatment and prophylaxis of illnesses that are associated with a microglia activation.